Guillaume Richard‐Carpentier

Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

Guillaume Richard‐Carpentier, Elias Jabbour, Nicholas J. Short et al. · Clinical Lymphoma Myeloma & Leukemia · 2019 · 123 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +10

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

Irene Gañán‐Gómez, Hui Yang, Feiyang Ma et al. · Nature Medicine · 2022 · 76 citations · Full text

Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML

Swati Garg, Armando Reyes‐Palomares, Lixiazi He et al. · Blood · 2019 · 65 citations · Full text

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial

Elias Jabbour, Guillaume Richard‐Carpentier, Yuya Sasaki et al. · The Lancet Haematology · 2020 · 63 citations

Hematological Malignancy, Frontline Therapy, Oncology +11

Outcomes of acute lymphoblastic leukemia with <i>KMT2A</i> (<i>MLL</i>) rearrangement: the MD Anderson experience

Guillaume Richard‐Carpentier, Hagop M. Kantarjian, Guilin Tang et al. · Blood Advances · 2021 · 52 citations · Full text

Mixed-phenotype Acute Leukemia, Immunology, Pathology +19